PYX-201 has gained FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

The US Food and Drug Administration (FDA) has granted fast track designation to Pyxis Oncology’s antibody-drug conjugate (ADC ...

Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...

Pyxis Oncology (PYXS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of ...

Pyxis Oncology (PYXS) stock rises as the FDA issues fast track designation for its lead asset PYX-201 in head and neck cancer ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® (pembrolizumab) in multiple solid tumors - Phase 1 ...

(RTTNews) - Pyxis Oncology, Inc. (PYXS), a clinical-stage company developing innovative cancer therapies, on Tuesday announced the initiation of a Phase 1/2 combination trial for PYX-201 ...

Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® (pembrolizumab) in multiple solid tumors - Phase ...